Effects of fenofibrate or eiocosapentaenoic acid(EPA) on glucose metabolism, fat distribution, adipocytokines and inflammatory cytokines in type 2 Diabetes.

Phase 4

• Conditions: type 2 Diabetes

• Registration Number: JPRN-UMIN000000969
• Lead Sponsor: Kobe University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-01-07
• Study Completion: 2010-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1. Severe hypercholesterolemia(LDL>140mg/dl) 2. Severe deficiency of insulin secretion 3. Severe renal dysfunction (serum creatinin>2.0mg/dl) 4. Severe liver dysfunction (AST, ALT>50IU/ml) 5. Severe herat failure 6. History of hypersensitivity to pioglitazone or metformin. 7. During the pregnancy and nursing 8. Inadequately BS contrilled (FBG>150mg/dl) 9. Inadequate to entry this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Evaluation of the effects on glucose metabolism and insulin sensitivity calculated with oral glucose tolerance test before and after 12 weeks treatment. 2. Measurement of the amount visceral fat, intramyocellular lipid content(IMCL) and hepatic lipid content(HLC) before and after 12 weeks treatment.

Secondary Outcome Measures

Name	Time	Method
3. Measurement of HbA1c, total-cholesterol, LDL-cholesterol, triglyceride, FFA, oxidized LDL, Lipoprotein(a), remnant-like particle lipoorotein(RLP), adipocytokines, inflammatory cytokines, oxidative stress marker before and after 12 weeks treatment. 4. Measurement of body weight and waist before and after 12 weeks treatment.